Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADiTx Therapeutics

2.21
+0.06002.79%
Pre-market: 2.220.0099+0.45%08:15 EDT
Volume:113.05K
Turnover:247.24K
Market Cap:2.56M
PE:0.00
High:2.25
Open:2.15
Low:2.05
Close:2.15
Loading ...

ADiTx Therapeutics trading halted, volatility trading pause

TIPRANKS
·
19 Mar

US Equities Markets End Lower Tuesday as Federal Reserve Kicks Off Policy Meeting

MT Newswires Live
·
19 Mar

Equity Markets Fall Amid Selloff in Technology

MT Newswires Live
·
19 Mar

Aditxt Shares Up After Acquisition Target Appili Files Funding Plans

MT Newswires Live
·
19 Mar

Shares of Aditxt Jump 86% After Appili Takeover Deadline Extended

THOMSON REUTERS
·
18 Mar

Dow Dips Over 200 Points; US Industrial Production Increases More than Expected

Benzinga
·
18 Mar

BRIEF-Appili Therapeutics Announces Submission Of US Federal Government Funding Proposals And Provides Corporate And Aditxt Transaction Update

Reuters
·
18 Mar

Appili Therapeutics Inc - Four New Funding Proposals, Totalling US$117.5 Mln, Submitted for Review

THOMSON REUTERS
·
18 Mar

Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

GlobeNewswire
·
18 Mar

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Business Wire
·
17 Mar

ADiTx Therapeutics trading halted, news pending

TIPRANKS
·
15 Mar

Crude Oil Falls 1%; Dollar General Posts Upbeat Sales

Benzinga
·
14 Mar

Nasdaq Down Over 100 Points; US Producer Inflation Stalls In February

Benzinga
·
13 Mar

US Stocks Likely To Open Lower After A Brief Respite: 'Add Exposure To Equities' Amid Pullback, Says Expert

Benzinga
·
13 Mar

Aditxt’s Adimune to ship substances for product formulation of of ADI-100

TIPRANKS
·
06 Mar

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of Adi-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

THOMSON REUTERS
·
06 Mar

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Business Wire
·
06 Mar

Aditxt subsidiary Persanta engages Dominary Securities for IPO

TipRanks
·
22 Feb

BRIEF-Aditxt Co's Unit Pearsanta Engaged Dominari Securities Llc As Lead Underwriter For Pearsanta's Planned IPO

Reuters
·
21 Feb

Aditxt: Co's Unit Pearsanta Engaged Dominari Securities Llc as Lead Underwriter for Pearsanta's Planned IPO

THOMSON REUTERS
·
21 Feb